PARP inhibitor Clinical Trials

5 actively recruiting trials

▲ +1 trial since June 2026

Also known as: Cohort 17 (homologous-recombination-deficient), Olaparib

Pipeline

Phase 2: 4Phase 2/3: 1

Top Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
Shanghai Gynecologic Oncology Group1
Peking Union Medical College1
N.N. Alexandrov National Cancer Centre1
Fudan University1

Indications

Cancer5
Ovarian Cancer2
Primary Peritoneal Carcinoma1
Precision Therapy1
Salivary Gland Carcinoma1

Other5 trials

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Phase 2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Phase 2

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.